Skip to main content

Facilitated recruitment of mesenchymal stromal cells by bone marrow concentrate and platelet rich plasma

Cornell Affiliated Author(s)

Author

H.L. Holmes
B. Wilson
J.P. Goerger
J.L. Silverberg
Itai Cohen
W.R. Zipfel
L.A. Fortier

Abstract

Background Biologics containing growth factors are frequently used to enhance healing after musculoskeletal injuries. One mechanism of action is thought to be though the ability of biologics to induce homing and migration of endogenous mesenchymal stromal cells (MSCs) to a target tissue. However, the ability of biologics to stimulate chemotaxis (directed migration of cells) and chemokinesis (increase rate of cell migration) of MSCs is unknown. Hypothesis/Purpose The aim of this study was to directly compare the ability of biologics including platelet rich plasma (PRP) and bone marrow concentrate (BMC) to induce MSC migration. The hypothesis was that leukocyte-low platelet rich plasma (Llo PRP) would induce migration to a greater extent than leukocyte-high platelet rich plasma (Lhi PRP) or BMC. Methods Bone marrow-derived MSCs were isolated from 8 horses. Migration of MSCs toward a biologic (BMC, Llo PRP, and Lhi PRP) or the positive control platelet derived growth factor (PDGF) was continuously traced and measured for 24hrs using time-lapse microscopy and a microfluidics device. Cell migration, chemotaxis and chemokinesis were determined by measurements of displacement, number of cells migrated, and cell flux. Results All biologics resulted in a significantly greater percentage of MSCs migrated compared to the positive control (PDGF). MSCs migrated further toward BMC compared to Llo PRP. Cell migration, measured as cell flux, was greater toward BMC and Lhi PRP than Llo PRP. Conclusion The biologics BMC and Lhi PRP elicit greater chemotaxis and chemokinesis of MSCs than Llo PRP. However, all biologics recruited the same number of MSCs suggesting that differences in other regenerative effects, such as growth factor concentration, between biologics should be strongly considered when choosing a biologic for treatment of musculoskeletal injuries. The results of this study have the potential to reduce the need, risks, and costs associated with MSC culture and delivery. © 2018 Holmes et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Date Published

Journal

PLoS ONE

Volume

13

Issue

3

URL

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85044294945&doi=10.1371%2fjournal.pone.0194567&partnerID=40&md5=83baeb454b732fe63d510177b408e6c2

DOI

10.1371/journal.pone.0194567

Research Area

Group (Lab)

Itai Cohen Group

Funding Source

T32RR018269
C028097

Download citation